文献速递中医内科中医康复中药与中成药合理使用

中医药治疗与预防COVID-19及康复的证据映射研究

Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: An evidence mapping study.
PubMed 文献 · Front Pharmacol · 2023-01-19

本研究采用证据映射方法,检索9个电子数据库及多个临床试验注册平台等,纳入126项研究(76项RCT和50项SR),评估中医药在COVID-19治疗、预防和康复中的证据。结果显示中医药在改善22项结局上一致阳性且未显著影响4项结局,但仅9项研究(7.14%)为高质量,证据数量和质量有限。

要点

  • 中医药在COVID-19治疗、预防和康复中显示潜在疗效和安全性。
  • 仅7.14%的研究为高质量,证据整体质量偏低。
  • 特定干预对个体结局的效果仍需进一步评估。

核心结论

  • 中医药在COVID-19治疗、预防和康复中显示潜在疗效和安全性,但证据数量有限且质量不高。

研究设计与样本

  • 采用证据映射方法,检索9个电子数据库、WHO ICTRP、ClinicalTrials.gov、灰色文献等至2022年3月23日,纳入126项研究(76项RCT和50项SR)。

主要发现

  • 76项RCT涉及59个干预类别和57个疗效结局,所有相关试验一致显示中医药显著改善22项结局,未显著影响4项结局。
  • 50项SR涉及9个干预类别和27个疗效结局,其中2项报告一致阳性结局,2项报告一致阴性结局。
  • 45项RCT和38项SR调查不良事件,其中39项RCT和30项SR显示无严重不良事件或组间无显著差异。
  • 仅9项研究(7.14%)为高质量:4项RCT评为低偏倚风险,5项SR评为高质量。

关键数值与推荐

  • 纳入研究分类:治疗组53项RCT和50项SR(81.75%),康复组20项RCT(15.87%),预防组3项RCT(2.38%)。

临床怎么用

  • 中医药可用于COVID-19治疗、预防和康复,但需结合证据质量和个体化评估。
  • 临床决策时应关注高质量证据的缺乏,并进一步评估特定干预对个体结局的效果。

局限性

  • 可用研究数量有限且质量差,当前临床评价标准对中医药的适用性可能存在担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The potential effectiveness of traditional Chinese medicine (TCM) against "epidemic diseases" has highlighted the knowledge gaps associated with TCM in COVID-19 management. This study aimed to map the matrix for rigorously assessing, organizing, and presenting evidence relevant to TCM in COVID-19 management. Methods: In this study, we used the methodology of evidence mapping (EM). Nine electronic databases, the WHO International Clinical Trials Registry Platform (ICTRP) Search Portal, ClinicalTrials.gov, gray literature, reference lists of articles, and relevant Chinese conference proceedings, were searched for articles published until 23 March 2022. The EndNote X9, Rayyan, EPPI, and R software were used for data entry and management. Results: In all, 126 studies, including 76 randomized controlled trials (RCTs) and 50 systematic reviews (SRs), met our inclusion criteria. Of these, only nine studies (7.14%) were designated as high quality: four RCTs were assessed as "low risk of bias" and five SRs as "high quality." Based on the research objectives of these studies, the included studies were classified into treatment (53 RCTs and 50 SRs, 81.75%), rehabilitation (20 RCTs, 15.87%), and prevention (3 RCTs, 2.38%) groups. A total of 76 RCTs included 59 intervention categories and 57 efficacy outcomes. All relevant trials consistently demonstrated that TCM significantly improved 22 outcomes (i.e., consistent positive outcomes) without significantly affecting four (i.e., consistent negative outcomes). Further, 50 SRs included nine intervention categories and 27 efficacy outcomes, two of which reported consistent positive outcomes and two reported consistent negative outcomes. Moreover, 45 RCTs and 38 SRs investigated adverse events; 39 RCTs and 30 SRs showed no serious adverse events or significant differences between groups. Conclusion: This study provides evidence matrix mapping of TCM against COVID-19, demonstrating the potential efficacy and safety of TCM in the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients, and also addresses evidence gaps. Given the limited number and poor quality of available studies and potential concerns regarding the applicability of the current clinical evaluation standards to TCM, the effect of specific interventions on individual outcomes needs further evaluation.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li Y, Qin Y, Chen N, et al. Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: An evidence mapping study. Front Pharmacol. 2023. PMID: 36744266. doi:10.3389/fphar.2023.1069879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。